Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus MYCELEX G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus MYCELEX G.
MICONAZOLE 7 vs MYCELEX-G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily for 7 days or 200 mg once daily for 3 days; or 500 mg single dose. Also available as 1% vaginal cream, 1 applicatorful (5 g) intravaginally once daily for 7-14 days.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Biphasic: initial half-life ~30 minutes, terminal half-life ~30 hours; clinical significance: supports once-daily dosing for topical/vaginal formulations.
Primarily fecal (~50%) and renal (~<1% unchanged)
Primarily hepatic metabolism; about 80-90% of dose excreted as metabolites in feces via biliary excretion, less than 1% unchanged in urine.
Category A/B
Category C
Antifungal
Antifungal